151751-Najiba-Chargi

227 Systemic therapy: skeletal muscle mass and bioradiotherapy Table 4 shows the univariate and multivariate Cox regression analysis for the association with DFS. The univariate analysis showed that none of the clinically relevant variables had signifi - cant prognostic value for DFS. However, BMI (HR 0.22; 95% CI 0.05-1.00; p = 0.05) and weight loss six months prior to diagnosis (HR 2.56; 95% CI 0.99-6.57; p = 0.05) did demonstrate a p-value close to statistically significant. Low SMM, BMI, and weight loss six months prior to diagnosis were entered into the multivariate analysis. In the multivariate analysis, none of the entered variables demonstrated a statistically significant prognostic value for DFS. Table 4. Univariate and multivariate analysis of prognostic factors for disease-free survival Variable Disease-free survival Univariate analysis a Multivariate analysis b HR 95% CI p-value HR 95% CI p-value Gender 1.39 0.55-3.48 0.49 Age 0.98 0.93-1.03 0.39 Weight loss 6 months prior None ≤ 10% > 10% Ref. 1.537 2.556 0.58-4.10 0.99-6.57 0.39 0.05 Ref. 1.49 2.04 0.55-4.08 0.72-5.78 0.43 0.18 Body Mass Index (kg/m 2 ) 20-24.9 < 20 25-29.9 ≥ 30 Ref. 0.90 0.22 0.75 0.36-2.26 0.05-1.00 0.24-2.36 0.83 0.05 0.62 0.74 0.31 2.21 0.28-1.94 0.07-1.44 0.47-10.57 0.54 0.14 0.32 ACE-27 score c None Mild Moderate Severe Ref. 0.95 1.12 1.15 0.19-4.71 0.24-5.22 0.24-5.46 0.95 0.88 0.86 TNM-stage Stage 1 Stage 2 Stage 3 Stage 4 Ref. 0.45 0.18 0.45 0.03-7.16 0.02-2.01 0.06-3.35 0.57 0.16 0.43 HPV status d 0.39 0.07-1.28 0.10 Low SMM 2.42 0.72-8.11 0.15 3.79 0.71-20.12 0.12 a Cox regression analysis, b Multivariate cox regression (Backward Wald model), c ACE-27 = Adult Comorbidity Evaluation, d HPV = Human Papillomavirus, ** Correlation is significant at the 0.01 level (2-tailed), * Correlation is significant at the 0.05 level (2-tailed) OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL Figures 3 and 4 show the Kaplan Meier Survival curves and number at risk tables for patients with and without low SMM. As can be seen in figure 3, patients with low SMM have a lower median OS (18.48 months; IQR 9.04-40.26) compared to patients without low SMM (34.66 12